Dr. James Shuler
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Unfortunately, it is also the most aggressive primary brain tumor. Even after neurosurgical resection of the tumor, the patient’s prognosis remains dismal. Surgery by itself is not curative, and thus adjuvant therapy is classically utilized. Since 1978, the standard of care for newly diagnosed glioblastoma includes surgical resection, followed by radiotherapy and chemotherapy. Regardless of multimodal treatment, almost all patients experience tumor progression. There is no established standard of care for recurrent glioblastoma, which emphasizes the importance of supportive and palliative care. The goal of extending lifespan must be balanced with the goal of maintaining a good quality of life. Ultimately, glioblastoma remains a heartbreaking diagnosis, with limited survival and poor treatment options. This article reviews the current approach to treatment of GBM and discusses the ongoing efforts to improve patient outcomes.
Lane LA. A Clinical Review of the Current Management of Glioblastoma Multiforme (GBM). Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.